Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

1.

Colonic delivery of docosahexaenoic acid improves impaired glucose tolerance via GLP-1 secretion and suppresses pancreatic islet hyperplasia in diabetic KK-A(y) mice.

Shida T, Kamei N, Takeda-Morishita M, Isowa K, Takayama K.

Int J Pharm. 2013 Jun 25;450(1-2):63-9. doi: 10.1016/j.ijpharm.2013.04.029. Epub 2013 Apr 22.

PMID:
23618969
[PubMed - indexed for MEDLINE]
2.

Usefulness of colon targeted DHA and EPA as novel diabetes medications that promote intrinsic GLP-1 secretion.

Morishita M, Tanaka T, Shida T, Takayama K.

J Control Release. 2008 Dec 8;132(2):99-104. doi: 10.1016/j.jconrel.2008.09.001. Epub 2008 Sep 6.

PMID:
18804128
[PubMed - indexed for MEDLINE]
3.

Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.

Green BD, Lavery KS, Irwin N, O'harte FP, Harriott P, Greer B, Bailey CJ, Flatt PR.

J Pharmacol Exp Ther. 2006 Aug;318(2):914-21. Epub 2006 Apr 28.

PMID:
16648370
[PubMed - indexed for MEDLINE]
Free Article
4.

Glucagon-like peptide-1 and islet lipolysis.

Sörhede Winzell M, Ahrén B.

Horm Metab Res. 2004 Nov-Dec;36(11-12):795-803.

PMID:
15655711
[PubMed - indexed for MEDLINE]
5.

Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies.

Meece J.

Curr Med Res Opin. 2007 Apr;23(4):933-44. Review.

PMID:
17407650
[PubMed - indexed for MEDLINE]
6.

Docosahexanoic acid (DHA) improved glucose and lipid metabolism in KK-Ay mice with genetic non-insulin-dependent diabetes mellitus (NIDDM).

Shimura T, Miura T, Usami M, Ishihara E, Tanigawa K, Ishida H, Seino Y.

Biol Pharm Bull. 1997 May;20(5):507-10.

PMID:
9178930
[PubMed - indexed for MEDLINE]
7.

The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.

Lam NT, Kieffer TJ.

Minerva Endocrinol. 2002 Jun;27(2):79-93. Review.

PMID:
11961501
[PubMed - indexed for MEDLINE]
8.

Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse.

Bahrami J, Longuet C, Baggio LL, Li K, Drucker DJ.

Gastroenterology. 2010 Sep;139(3):857-68. doi: 10.1053/j.gastro.2010.05.006. Epub 2010 Jun 11.

PMID:
20546737
[PubMed - indexed for MEDLINE]
9.

Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.

Mu J, Petrov A, Eiermann GJ, Woods J, Zhou YP, Li Z, Zycband E, Feng Y, Zhu L, Roy RS, Howard AD, Li C, Thornberry NA, Zhang BB.

Eur J Pharmacol. 2009 Nov 25;623(1-3):148-54. doi: 10.1016/j.ejphar.2009.09.027. Epub 2009 Sep 16.

PMID:
19765579
[PubMed - indexed for MEDLINE]
10.

Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.

Pratley RE, Salsali A.

Curr Med Res Opin. 2007 Apr;23(4):919-31. Review.

PMID:
17407649
[PubMed - indexed for MEDLINE]
11.

Oral administration of corn zein hydrolysate stimulates GLP-1 and GIP secretion and improves glucose tolerance in male normal rats and Goto-Kakizaki rats.

Higuchi N, Hira T, Yamada N, Hara H.

Endocrinology. 2013 Sep;154(9):3089-98. doi: 10.1210/en.2012-2275. Epub 2013 Jun 24.

PMID:
23798598
[PubMed - indexed for MEDLINE]
12.

Combination of TS-021 with metformin improves hyperglycemia and synergistically increases pancreatic β-cell mass in a mouse model of type 2 diabetes.

Tajima A, Hirata T, Taniguchi K, Kondo Y, Kato S, Saito-Hori M, Ishimoto T, Yamamoto K.

Life Sci. 2011 Oct 24;89(17-18):662-70. doi: 10.1016/j.lfs.2011.08.005. Epub 2011 Aug 18.

PMID:
21872612
[PubMed - indexed for MEDLINE]
13.

Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance.

Byrne MM, Gliem K, Wank U, Arnold R, Katschinski M, Polonsky KS, Göke B.

Diabetes. 1998 Aug;47(8):1259-65.

PMID:
9703326
[PubMed - indexed for MEDLINE]
Free Article
14.

Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.

Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA.

Diabetes Care. 2003 Mar;26(3):791-8.

PMID:
12610039
[PubMed - indexed for MEDLINE]
15.

Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats.

Larsen PJ, Wulff EM, Gotfredsen CF, Brand CL, Sturis J, Vrang N, Knudsen LB, Lykkegaard K.

Diabetes Obes Metab. 2008 Apr;10(4):301-11. doi: 10.1111/j.1463-1326.2008.00865.x.

PMID:
18333889
[PubMed - indexed for MEDLINE]
16.

Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice.

Reimer MK, Holst JJ, Ahrén B.

Eur J Endocrinol. 2002 May;146(5):717-27.

PMID:
11980629
[PubMed - indexed for MEDLINE]
Free Article
17.

Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.

Cuthbertson J, Patterson S, O'Harte FP, Bell PM.

Metabolism. 2011 Jan;60(1):52-6. doi: 10.1016/j.metabol.2010.01.001. Epub 2010 Feb 11.

PMID:
20152998
[PubMed - indexed for MEDLINE]
18.

Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery.

Chae SY, Jin CH, Shin HJ, Youn YS, Lee S, Lee KC.

Bioconjug Chem. 2008 Jan;19(1):334-41. Epub 2007 Dec 14.

PMID:
18078308
[PubMed - indexed for MEDLINE]
19.

Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.

Moritoh Y, Takeuchi K, Hazama M.

J Pharmacol Exp Ther. 2009 May;329(2):669-76. doi: 10.1124/jpet.108.148056. Epub 2009 Feb 10.

PMID:
19208898
[PubMed - indexed for MEDLINE]
Free Article
20.

Mosapride citrate, a 5-HT₄ receptor agonist, increased the plasma active and total glucagon-like peptide-1 levels in non-diabetic men.

Aoki K, Kamiyama H, Masuda K, Togashi Y, Terauchi Y.

Endocr J. 2013;60(4):493-9. Epub 2012 Dec 18.

PMID:
23257734
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk